Share on Pinterest Research shows that people who stop taking GLP-1 medications regain weight within 2 years. Image Credit: Tatsiana Volkava/Getty Images A new study has found that people regain ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes and cancer had reduced risk ...

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. This rate of weight regain is significantly faster than ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research letter published online Dec. 10 in JAMA Surgery.

GLP-1 RA use was associated with significantly lower epilepsy risk, with protective associations seen at 1, 3, and 5 years. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon ...

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are calling for more research. Reading time 2 minutes Every drug has its risks, no ...

Sabrina Chazen followed the rules. She cut her carbs, counted her calories and walked every day. But after four disciplined months, the scale hardly moved. “I lost maybe a pound,” the 39-year-old ...

Danish researchers were examining the use of medications during and after pregnancy when they noticed a clear trend: The number of women using weight-loss drugs like Ozempic and Wegovy soon after ...

Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up. Eli Lilly should remain the top player, though, and ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...

A new real-world study reveals that advanced GLP-1 therapies, including semaglutide and tirzepatide, provide comparable glycemic control while offering superior weight benefits compared to metformin ...